Track topics on Twitter Track topics that are important to you
Antengene, a Shanghai novel drug biopharma, has in-licensed global rights to a novel cancer treatment from AstraZeneca. The company said AstraZeneca has filed an open IND application for AZD0364, a selective small molecule ERK1/2 inhibitor, in the US for multiple solid tumor cancers. ERK is a key component of the Ras-Raf-MEK-ERK (RAS/MAPK) pathway, which promotes tumor cell growth and survival. Antengene expects the candidate will be effective as a monotherapy and in combination with other of its portfolio drugs. Details of the agreement were not disclosed. More details....
Stock Symbol: (NYSE: AZN)
Share this with colleagues:
Original Article: Antengene Acquires Global Rights to AstraZeneca Cancer CandidateNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...